Elekta, IBM Watson Health join to work on oncology

Elekta, a developer of equipment and software used to provide care to oncology patients, is partnering with IBM Watson Health to bring artificial intelligence solutions to comprehensive oncology care.

Under terms of an agreement, Stockholm-based Elekta will sell Watson for Oncology as a clinical decision support solution that will be paired with Elekta’s digital cancer care solutions, including its oncology information system.

Executives for Elekta says it plans to offer the joint solution to healthcare providers in the U.S., Brazil, some large European and Asian markets, as well as India and Australia.

“Joining forces with IBM Watson Health positions Elekta as the first radiation therapy company to offer capabilities that combine conventional health information systems with artificial intelligence and cognitive cloud computing,” says Richard Hausmann, CEO of Elekta.

 “Our goal is to bring cutting edge artificial intelligence technology to the cancer care continuum, including treatment planning, enabling evidence-based treatment recommendations for every patient regardless of where they are treated,” Hausmann adds.


Watson for Oncology was developed by IBM in collaboration with Memorial Sloan Kettering Cancer Center in New York. It can summarize key medical attributes of a patient, and provide information to oncologists to help them deliver treatment options based on training from MSK oncologists.

Watson for Oncology ranks the treatment options, linking to peer-reviewed studies that have been curated by Memorial Sloan Kettering. Watson for Oncology also provides a large body of medical literature for a physician to consider, drawing on more than 300 medical journals, more than 200 textbooks and nearly 15 million pages of text to provide insights about different treatment options.

“Oncologists around the world rely on MOSAIQ to support the treatment pathway, and we are eager to extend Watson for Oncology to more physicians and patients globally through Elekta’s sophisticated digital oncology solutions,” said Lisa Rometty,, vice president of oncology and life sciences, IBM Watson Health.

Original Source: https://www.healthdatamanagement.com/news/artificial-intelligence-from-ibm-watson-will-influence-patient-treatment-options

Original Author: Fred Bazzoli

Original Date: Feb 2 2018

Leave a Reply

Your email address will not be published. Required fields are marked *